{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:02:30Z","timestamp":1772438550451,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T00:00:00Z","timestamp":1482278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T00:00:00Z","timestamp":1482278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY012609"],"award-info":[{"award-number":["EY012609"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00109-016-1498-9","type":"journal-article","created":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T08:39:20Z","timestamp":1482309560000},"page":"417-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization"],"prefix":"10.1007","volume":"95","author":[{"given":"Mingbing","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jikui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth D.","family":"Fortmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmood","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean F.","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg L.","family":"Semenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Campochiaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,21]]},"reference":[{"key":"1498_CR1","first-page":"933","volume":"99","author":"R Klein","year":"1992","unstructured":"Klein R, Klein BE, Linton KL (1992) Prevalence of age-related maculopathy. The Beaver Dam Eye Study Ophthalmology 99:933\u2013943","journal-title":"The Beaver Dam Eye Study Ophthalmology"},{"key":"1498_CR2","first-page":"293","volume-title":"Diabetes in America National Institutes of Health","author":"R Klein","year":"1995","unstructured":"Klein R, Klein B (1995) Vision disorders in diabetes. In: Group NDD (ed) Diabetes in America National Institutes of Health. Washington, D.C., pp. 293\u2013330"},{"key":"1498_CR3","first-page":"182","volume":"40","author":"H Ozaki","year":"1999","unstructured":"Ozaki H, Yu A, Della N, Ozaki K, Luna JD, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL et al (1999) Hypoxia inducible factor-1a is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 40:182\u2013189","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1498_CR4","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1161\/01.RES.0000102937.50486.1B","volume":"93","author":"BD Kelly","year":"2003","unstructured":"Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA, Semenza GL (2003) Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 93:1074\u20131081","journal-title":"Circ Res"},{"key":"1498_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/jcp.20525","volume":"206","author":"SA Vinores","year":"2006","unstructured":"Vinores SA, Xiao WH, Aslam S, Shen J, Oshima Y, Nambu H, Liu H, Carmeliet P, Campochiaro PA (2006) Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol 206:749\u2013758","journal-title":"J Cell Physiol"},{"key":"1498_CR6","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1096\/fj.09-145664","volume":"24","author":"T Yoshida","year":"2010","unstructured":"Yoshida T, Zhang H, Iwase T, Shen J, Semenza G, Campochiaro PA (2010) Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J 24:1759\u20131767","journal-title":"FASEB J"},{"key":"1498_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jconrel.2013.10.008","volume":"172","author":"T Iwase","year":"2013","unstructured":"Iwase T, Fu J, Yoshida T, Muramatusu D, Miki A, Hashida N, Lu L, Oveson B, Lime e Silva R, Seidel C et al (2013) Sustained delivery of a HIF-1 antagonist for ocular neovascularization. J Control Release 172:625\u2013633","journal-title":"J Control Release"},{"key":"1498_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","volume":"49","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA (2015) Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res 49:67\u201381","journal-title":"Prog Retin Eye Res"},{"key":"1498_CR9","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"1498_CR10","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD et al (2012) Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548","journal-title":"Ophthalmology"},{"key":"1498_CR11","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.ajo.2006.06.068","volume":"142","author":"QD Nguyen","year":"2006","unstructured":"Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA (2006) Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142:961\u2013969","journal-title":"Am J Ophthalmol"},{"key":"1498_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ et al (2012) Ranibizumab for diabetic macular edema. Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789\u2013801","journal-title":"Ophthalmology"},{"key":"1498_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/mt.2008.10","volume":"16","author":"PA Campochiaro","year":"2008","unstructured":"Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon S et al (2008) Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator. Molec Ther 16:791\u2013799","journal-title":"Molec Ther"},{"key":"1498_CR14","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, Group BS (2010) Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study. Ophthalmology 117:1102\u20131112","journal-title":"Ophthalmology"},{"key":"1498_CR15","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP, Gray S, Rundle AC, Li Z, Rubio RG, Murahashi WY, Group CS (2010) Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion:6-month results of the phase III CRUISE study. Ophthalmology 117:1124\u20131133","journal-title":"Ophthalmology"},{"key":"1498_CR16","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/archophthalmol.2012.1043","volume":"130","author":"MS Ip","year":"2012","unstructured":"Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS (2012) Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 130:1145\u20131152","journal-title":"Arch Ophthalmol"},{"key":"1498_CR17","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","volume":"168","author":"N Jo","year":"2006","unstructured":"Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168:2036\u20132053","journal-title":"Am J Pathol"},{"key":"1498_CR18","first-page":"553","volume":"17","author":"A Dong","year":"2014","unstructured":"Dong A, Seidel C, Snell D, Ekawardhani S, Ahlskog JK, Baumann M, Shen J, Iwase T, Tian J, Stevens R et al (2014) Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis 17:553\u2013562","journal-title":"Angiogenesis"},{"key":"1498_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7","volume":"184","author":"SF Hackett","year":"2000","unstructured":"Hackett SF, Ozaki H, Strauss RW, Wahlin K, Suri C, Maisonpierre P, Yancopoulos G, Campochiaro PA (2000) Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol 184:275\u2013284","journal-title":"J Cell Physiol"},{"key":"1498_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/jcp.10128","volume":"192","author":"SF Hackett","year":"2002","unstructured":"Hackett SF, Wiegand SJ, Yancopoulos G, Campochiaro P (2002) Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell Physiol 192:182\u2013187","journal-title":"J Cell Physiol"},{"key":"1498_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1534-5807(02)00217-4","volume":"3","author":"NW Gale","year":"2002","unstructured":"Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte M, Jackson D et al (2002) Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Devel Cell 3:411\u2013423","journal-title":"Devel Cell"},{"key":"1498_CR22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1096\/fj.04-2209fje","volume":"19","author":"Y Oshima","year":"2005","unstructured":"Oshima Y, Oshima S, Nambu H, Kachi S, Takahashi K, Umeda N, Shen J, Dong A, Apte RS, Duh E et al (2005) Different effects of angiopoietin 2 in different vascular beds in the eye; new vessels are most sensitive. FASEB J 19:963\u2013965","journal-title":"FASEB J"},{"key":"1498_CR23","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1096\/fj.06-7359com","volume":"21","author":"R Lima e Silva","year":"2007","unstructured":"Lima e Silva R, Shen J, Hackett SF, Kachi S, Akiyama H, Kiuchi K, Yokoi K, Hatara C, McLauer T, Aslam S et al (2007) The SDF-1\/CXCR4 ligand\/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J 21:3219\u20133230","journal-title":"FASEB J"},{"key":"1498_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ophtha.2015.09.004","volume":"123","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Eliott D, Well JA, Prenner JL, Papp A, Patel S (2016) A phase 1 sutdy of intravitreous E10030 in combination with ranibizumab in neovascular age-related macular degeneration. Ophthalmology 123:78\u201385","journal-title":"Ophthalmology"},{"key":"1498_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ophtha.2014.09.023","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Sophie R, Tolentino M, Miller DM, Browning D, Boyer DS, Heier JS, Gambino L, Withers B, Brigell M et al (2015) Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology 122:545\u2013554","journal-title":"Ophthalmology"},{"key":"1498_CR26","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.ophtha.2016.04.025","volume":"123","author":"PA Campochiaro","year":"2016","unstructured":"Campochiaro PA, Khanani A, Singer M, Patel S, Boyer D, Dugel P, Kherani S, Withers B, Gambino L, Peters K et al (2016) Enhanced benefit in diabetic macular edema from AKB-9778 Tie2 activation combined with vascular endothelial growth factor suppression. Ophthalmology 123:1722\u20131730","journal-title":"Ophthalmology"},{"key":"1498_CR27","doi-asserted-by":"publisher","first-page":"19579","DOI":"10.1073\/pnas.0809763105","volume":"105","author":"H Zhang","year":"2008","unstructured":"Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R et al (2008) Digoxin and other cardiac glycosides inhibit HIF-1alpha sythesis and block tumor growth. Proc Natl Acad Sci U S A 105:19579\u201319586","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1498_CR28","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1073\/pnas.0812801106","volume":"106","author":"K Lee","year":"2009","unstructured":"Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL (2009) Antracycline chemotherpy inhibits HIF-1 transcriptional activity and tumor induced mobilizatio of circulating angiogenic cells. Proc Natl Acad Sci U S A 106:2353\u20132358","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1498_CR29","doi-asserted-by":"publisher","first-page":"17910","DOI":"10.1073\/pnas.0909353106","volume":"106","author":"K Lee","year":"2009","unstructured":"Lee K, Zhang H, Qlan DZ, Rey S, Liu JO, Semenza GL (2009) Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A 106:17910\u201317915","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1498_CR30","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1096\/fj.05-5046fje","volume":"20","author":"J Shen","year":"2006","unstructured":"Shen J, Yang XR, Xiao WH, Hackett SF, Sato Y, Campochiaro PA (2006) Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J 20:723\u2013725","journal-title":"FASEB J"},{"key":"1498_CR31","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S0002-9440(10)65753-7","volume":"153","author":"T Tobe","year":"1998","unstructured":"Tobe T, Ortega S, Luna JD, Ozaki H, Okamoto N, Derevjanik NL, Vinores SA, Basilico C, Campochiaro PA (1998) Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 153:1641\u20131646","journal-title":"Am J Pathol"},{"key":"1498_CR32","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/0005-2787(76)90049-6","volume":"447","author":"JW Levinson","year":"1976","unstructured":"Levinson JW, Desostoa A, Liebes LF, McCormick JJ (1976) Fluorescent labeling of DNA in solution with covalently bound acriflavin. Biochim Biophys Acta 447:260\u2013273","journal-title":"Biochim Biophys Acta"},{"key":"1498_CR33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1177\/25.11.597361","volume":"25","author":"JW Levinson","year":"1977","unstructured":"Levinson JW, Maher VM, JJ MC (1977) Purification of commercil acriflavine by sephadex LH-20 column chromatography. J Histochem Cytochem 25:1275\u20131277","journal-title":"J Histochem Cytochem"},{"key":"1498_CR34","doi-asserted-by":"publisher","first-page":"11300","DOI":"10.1073\/pnas.0604056103","volume":"103","author":"K Komeima","year":"2006","unstructured":"Komeima K, Rogers BS, Lu L, Campochiaro PA (2006) Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci U S A 103:11300\u201311305","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1498_CR35","first-page":"101","volume":"35","author":"LEH Smith","year":"1994","unstructured":"Smith LEH, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101\u2013111","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1498_CR36","doi-asserted-by":"publisher","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","volume":"92","author":"LP Aiello","year":"1995","unstructured":"Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LEH (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 92:10457\u201310461","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1498_CR37","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1073\/pnas.92.3.905","volume":"92","author":"EA Pierce","year":"1995","unstructured":"Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LEH (1995) Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 92:905\u2013909","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1498_CR38","first-page":"3158","volume":"41","author":"N Kwak","year":"2000","unstructured":"Kwak N, Okamoto N, Wood JM, Campochiaro PA (2000) VEGF is an important stimulator in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41:3158\u20133164","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1498_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/jcp.10246","volume":"195","author":"Y Saishin","year":"2003","unstructured":"Saishin Y, Saishin Y, Takahashi K, Lima Silva R, Hylton D, Rudge JS, Wiegand SJ, Campochiaro PA (2003) VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:241\u2013248","journal-title":"J Cell Physiol"},{"key":"1498_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1098\/rspb.1922.0025","volume":"93","author":"CH Browning","year":"1922","unstructured":"Browning CH, Cohen JB, Gaunt R, Gulbransen R (1922) Relationships between antiseptic action and chemical constitution with special reference to compounds of the pyridine, quinoline, acridine, and phenazine series. Proc Royal Soc 93:329\u2013366","journal-title":"Proc Royal Soc"},{"key":"1498_CR41","doi-asserted-by":"crossref","unstructured":"Assinder EW (1936) Acriflavine as a urinary antiseptic. Lancet 227","DOI":"10.1016\/S0140-6736(00)56423-X"},{"key":"1498_CR42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jcp.21426","volume":"216","author":"J Doukas","year":"2008","unstructured":"Doukas J, Mahesh S, Umeda N, Kachi S, Akiyama H, Yokoi K, Cao J, Chen Z, Dellamary L, Tam B et al (2008) Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovasculaization and retinal edema. J Cell Physiol 216:29\u201337","journal-title":"J Cell Physiol"},{"key":"1498_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","volume":"28","author":"SR Patel","year":"2011","unstructured":"Patel SR, Lin AS, Edelhauser HF, Prausnitz MR (2011) Suprachoroidal drug delivery to the back of the eye using hollow needles. Pharm Res 28:166\u2013176","journal-title":"Pharm Res"},{"key":"1498_CR44","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1167\/iovs.12-9872","volume":"53","author":"SR Patel","year":"2012","unstructured":"Patel SR, Berezovsky DE, McCarey BE, Zarnitsyn V, Edelhauser HF, Prausnitz MR (2012) Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci 53:4433\u20134441","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1498_CR45","doi-asserted-by":"publisher","first-page":"10418","DOI":"10.1021\/ja402993u","volume":"135","author":"E Miranda","year":"2013","unstructured":"Miranda E, Nordgren IK, Male AL, Lawrence CE, Hoakwie F, Cuda F, Court W, Fox KR, Townsend PA, Packham GK et al (2013) A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J Am Chem Soc 135:10418\u201310425","journal-title":"J Am Chem Soc"},{"key":"1498_CR46","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s12274-016-1059-0","volume":"9","author":"M Broekgaarden","year":"2016","unstructured":"Broekgaarden M, Weijer R, Krekorian M, van den IJssel B, Kos M, Alles LK, van Wijk AC, Hazai E, van Gulik TM, Heger M (2016) Inhibition of hypoxia-inducible factor 1 with acriflavine sensitizes hypoxic tumor cells to photodynamic therapy with zinc phthalocyanine-encapsulating cationic liposomes. Nano Res 9:1639\u20131662","journal-title":"Nano Res"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-016-1498-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-016-1498-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-016-1498-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T16:18:59Z","timestamp":1589559539000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-016-1498-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,21]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1007\/s00109-016-1498-9","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,21]]},"assertion":[{"value":"11 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}